2/5
08:05 am
alms
Alumis to Participate in Upcoming February Investor Conferences
Low
Report
Alumis to Participate in Upcoming February Investor Conferences
1/22
07:48 am
alms
Alumis (NASDAQ:ALMS) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Low
Report
Alumis (NASDAQ:ALMS) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
1/21
08:42 am
alms
Alumis (NASDAQ:ALMS) was given a new $37.00 price target on by analysts at Loop Capital.
Low
Report
Alumis (NASDAQ:ALMS) was given a new $37.00 price target on by analysts at Loop Capital.
1/21
07:17 am
alms
Alumis (NASDAQ:ALMS) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock.
Low
Report
Alumis (NASDAQ:ALMS) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock.
1/21
06:06 am
alms
Alumis (NASDAQ:ALMS) was given a new $37.00 price target on by analysts at Chardan Capital.
Low
Report
Alumis (NASDAQ:ALMS) was given a new $37.00 price target on by analysts at Chardan Capital.
1/15
07:02 pm
alms
HC Wainwright & Co. Hikes Alumis Inc. (ALMS)'s Price Target To $40 From $20, Reiterates Buy Rating [Yahoo! Finance]
Low
Report
HC Wainwright & Co. Hikes Alumis Inc. (ALMS)'s Price Target To $40 From $20, Reiterates Buy Rating [Yahoo! Finance]
1/9
04:05 pm
alms
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Medium
Report
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
1/9
07:18 am
alms
Alumis (NASDAQ:ALMS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Alumis (NASDAQ:ALMS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/7
10:52 pm
alms
Alumis Announces Pricing of Upsized Public Offering of Common Stock
Low
Report
Alumis Announces Pricing of Upsized Public Offering of Common Stock
1/7
11:41 am
alms
Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise [Seeking Alpha]
Low
Report
Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise [Seeking Alpha]
1/7
08:02 am
alms
Alumis (NASDAQ:ALMS) had its price target raised by analysts at Guggenheim from $18.00 to $32.00. They now have a "buy" rating on the stock.
Medium
Report
Alumis (NASDAQ:ALMS) had its price target raised by analysts at Guggenheim from $18.00 to $32.00. They now have a "buy" rating on the stock.
1/7
07:18 am
alms
Alumis (NASDAQ:ALMS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Alumis (NASDAQ:ALMS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
1/6
07:01 pm
alms
Alumis (NASDAQ:ALMS) had its "outperform" rating reaffirmed by analysts at UBS Group AG.
Medium
Report
Alumis (NASDAQ:ALMS) had its "outperform" rating reaffirmed by analysts at UBS Group AG.
1/6
06:01 pm
alms
Alumis (NASDAQ:ALMS) was given a new $32.00 price target on by analysts at Leerink Partners.
Medium
Report
Alumis (NASDAQ:ALMS) was given a new $32.00 price target on by analysts at Leerink Partners.
1/6
05:04 pm
alms
Alumis (NASDAQ:ALMS) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Alumis (NASDAQ:ALMS) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
1/6
05:04 pm
alms
Alumis (NASDAQ:ALMS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Alumis (NASDAQ:ALMS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
1/6
04:12 pm
alms
Alumis Announces Proposed Public Offering of Common Stock
Medium
Report
Alumis Announces Proposed Public Offering of Common Stock
1/6
11:05 am
alms
Alumis (NASDAQ:ALMS) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Alumis (NASDAQ:ALMS) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
1/6
10:04 am
alms
Download the CNN app [CNN]
High
Report
Download the CNN app [CNN]
1/6
07:22 am
alms
Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program [Yahoo! Finance]
High
Report
Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program [Yahoo! Finance]
1/6
07:00 am
alms
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
High
Report
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
1/5
05:12 pm
alms
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis [Yahoo! Finance]
High
Report
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis [Yahoo! Finance]
1/5
05:00 pm
alms
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis
High
Report
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis
12/18
11:00 am
alms
Alumis (NASDAQ:ALMS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Alumis (NASDAQ:ALMS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/6
01:36 am
alms
Low
Report